Thyroid Cancer Treatment Market: By Cancer Type, Follicular Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer, and Others), Treatment Type, Radioactive Iodine Therapy, Thyroid Hormone Therapy, External Beam Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By Route of Administration, By End User, and Region Forecast 2020-2031
Thyroid Cancer Treatment Market size was valued at US$ 923.0 million in 2024 and is projected to reach US$ 1,709.0 million by 2031, growing at a CAGR of 9.2% from 2025-2031. Moreover, in the USA, the thyroid cancer treatment market size is projected to reach
US$ 533.2 million by 2031. ?Thyroid cancer, the most prevalent endocrine malignancy, has seen a significant rise in global incidence, leading to an increased demand for effective treatment options. In 2022, approximately 821,214 new cases were reported worldwide, with women accounting for about 74.86% of these cases. The age-standardized incidence rate (ASIR) was notably higher in women (13.60 per 100,000) compared to men (4.60 per 100,000). Eastern Asia recorded the highest ASIR at 23.10 per 100,000, while Western Africa had the lowest at 0.94 per 100,000. China alone contributed to 56.77% of global thyroid cancer cases and 24.35% of related deaths.
Projections indicate that by 2050, new cases could reach approximately 1.1 million, a 34.15% increase from 2022, with related deaths potentially rising by 89.58% to around 91,000. This escalating burden underscores the critical need for advancements in thyroid cancer treatments, including surgical interventions, radioactive iodine therapy, targeted therapies, and emerging immunotherapies. The market is poised for growth, driven by heightened awareness, improved diagnostic techniques, and the development of innovative treatment modalities to address the increasing patient population. ?
Based on the Cancer Type:
Papillary Thyroid Cancer (PTC) is the most dominant segment in the market, accounting for approximately 80% of all thyroid cancer cases, according to the American Cancer Society. Its high prevalence, favorable prognosis, and responsiveness to treatments like radioactive iodine contribute significantly to market share and therapeutic advancements.
Based on the Treatment Type:
Surgery, particularly thyroidectomy, is the dominant treatment segment in the market. It is often the first-line approach for most thyroid cancers, especially papillary and follicular types. According to the American Cancer Society, surgery offers high success rates, making it the cornerstone of thyroid cancer management globally.
Based on the Route of Administration:
The oral route of administration dominates the market due to the widespread use of oral targeted therapies like lenvatinib and sorafenib. This method offers greater patient convenience, improved adherence, and reduced hospital visits, making it a preferred choice for long-term treatment, especially in advanced and metastatic thyroid cancer cases.
Based on the End User:
Hospitals dominate the market due to their comprehensive healthcare infrastructure, access to multidisciplinary teams, and advanced diagnostic and therapeutic technologies. They are primary centers for surgical procedures, radioactive iodine therapy, and systemic treatments, ensuring holistic patient care, which drives higher patient volumes and makes hospitals the leading end-user segment.
Based on the Distribution Channel:
Hospital pharmacies dominate the market as they are the primary source for dispensing specialized medications, including radioactive iodine and targeted therapies. Their close integration with healthcare providers ensures timely and accurate treatment administration, enhancing patient outcomes and making them a crucial distribution channel in cancer care delivery
Study Period
2025-2031Base Year
2024CAGR
9.2%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The market is witnessing steady growth, primarily driven by the increasing global incidence of thyroid cancer. According to GLOBOCAN 2022 (WHO’s IARC), there were approximately 586,000 new cases of thyroid cancer globally, ranking it as the ninth most common cancer. The disease shows a higher prevalence among women, with a female-to-male ratio of about 3:1. This rising burden has heightened the demand for effective and targeted therapies. The U.S. FDA has granted full approval to advanced drugs like selpercatinib (Retevmo) for RET-altered thyroid cancers in both adults and children as young as two years.
Similarly, lenvatinib (Lenvima) remains a cornerstone for treating radioiodine-refractory differentiated thyroid cancer. Radioactive iodine (RAI) therapy also continues to play a pivotal role in standard treatment regimens, particularly after thyroidectomy, as recommended by the American Cancer Society. Moreover, the launch of the Thyroid Cancer Registry by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in 2025 marks a significant step toward collecting real-world evidence, supporting research, and improving patient outcomes. Together, these developments are fueling sustained growth in the market.
Despite advancements in targeted therapies and diagnostics, the market faces notable restraints that impact its broader adoption and patient outcomes. One major challenge is the high cost of targeted therapies, such as selpercatinib (Retevmo®) and lenvatinib (Lenvima®), which can exceed $20,000 per month, making them unreachable for uninsured or underinsured populations (FDA, American Cancer Society). Limited reimbursement and insurance coverage further worsen this issue in several regions. In addition, treatment side effects such as hypertension, diarrhea, fatigue, and liver dysfunction can reduce patient compliance and negatively affect quality of life.
For example, radioactive iodine therapy, commonly used in treatment, may cause long-term complications like salivary gland dysfunction and secondary malignancies. Another restraint is limited access to early diagnosis and advanced treatments in rural or low-resource settings, often leading to delayed care and poorer prognosis. According to the American Cancer Society, while the 5-year survival rate is high for localized cases (98%), it drops sharply for distant metastatic cases (59%) and is under 10% for anaplastic thyroid cancer. These challenges together hamper equitable access and optimal outcomes across patient demographics.
The market presents numerous opportunities driven by innovation in therapeutics and increasing global disease burden. Advancements in precision medicine and targeted therapy, particularly for RET and BRAF mutations, are opening new treatment pathways. The FDA’s full approval of selpercatinib (Retevmo®) in 2024 for advanced RET-mutant thyroid cancer, along with the success of lenvatinib (Lenvima®), highlights the growing potential of molecular-targeted drugs that offer improved efficacy and reduced side effects compared to older treatments. Moreover, increasing thyroid cancer incidence globally fuels demand.
The American Cancer Society estimated about 44,020 new cases in the U.S. alone in 2024, emphasizing the growing patient population. The launch of the SNMMI Thyroid Cancer Registry further supports clinical research by capturing real-world evidence on radiopharmaceutical therapies, enhancing innovation in radioactive iodine treatments. In addition, rising awareness, earlier diagnosis, and preference for non-surgical, outpatient treatments are driving demand for novel therapeutic approaches. Emerging markets in Asia-Pacific and Latin America also offer untapped potential due to improved healthcare infrastructure and increasing access to diagnostics and specialty care. Together, these factors create a promising outlook for companies innovating in thyroid cancer therapies.
The market is witnessing transformative trends driven by technological advances and personalized medicine. A prominent trend is the growing adoption of targeted therapies such as selpercatinib and lenvatinib, which are tailored to treat specific genetic mutations like RET and BRAF. These therapies offer improved outcomes and fewer side effects, reflecting the shift toward precision oncology. In addition, radiopharmaceutical therapies like radioactive iodine (RAI) are gaining momentum, supported by initiatives such as the SNMMI’s Thyroid Cancer Registry, which collects real-world data to enhance clinical practices. The trend toward minimally invasive and outpatient treatments is also reshaping the market. Innovations in drug delivery and radiation techniques are reducing hospitalization time and improving patient comfort.
Furthermore, increased incidence rates, due in part to improved imaging technologies, are resulting in earlier diagnoses. The American Cancer Society notes a steady rise in thyroid cancer cases, particularly small papillary thyroid cancers, which are often detected incidentally. Moreover, the integration of artificial intelligence (AI) and digital health platforms is transforming diagnostics and treatment planning, enhancing decision-making and patient monitoring. Together, these trends are propelling the market toward more efficient, effective, and patient-centric care models.
North America dominates the market, led primarily by the United States. This dominance is attributed to high disease prevalence, advanced healthcare infrastructure, and robust research funding. According to the American Cancer Society, an estimated 44,020 new cases of thyroid cancer were diagnosed in the U.S. in 2024, with women accounting for nearly three-quarters of these cases. The U.S. also benefits from the widespread availability of cutting-edge treatments such as radioactive iodine therapy and targeted therapies like selpercatinib (Retevmo®) and lenvatinib (Lenvima®), both approved by the FDA. The presence of leading cancer institutions such as Memorial Sloan Kettering Cancer Center and a strong focus on personalized medicine contribute significantly to market leadership.
The Asia-Pacific region is the fastest-growing market, driven by increasing awareness, government initiatives, and expanding healthcare access. Countries such as China, Japan, South Korea, and India are witnessing rising thyroid cancer incidence. According to Japan’s National Cancer Center, thyroid cancer ranks among the top ten most common cancers in Japanese women. In addition, rising healthcare expenditures and growth in diagnostic capabilities are improving early detection rates, while expanding pharmaceutical access is fueling regional market acceleration.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 923.0 million |
|
Market Size in 2031 |
US$ 1,709.0 million |
|
Market CAGR |
9.2% |
|
By Cancer Type |
|
|
By Treatment Type |
|
|
By Route of Administration |
|
|
By End User |
|
|
By Distribution Channel |
|
Download Free Sample Report
The thyroid cancer treatment market size was valued at US$ 923.0 million in 2024 and is projected to grow at a CAGR of 9.2% from 2025-2031.
• Rising Global Incidence of Thyroid Cancer • Advancements in Targeted Therapies • Improved Diagnostic and Screening Tools
• Expansion of Targeted and Precision Therapies • Growing Focus on Radiopharmaceutical Advancements • Emerging Markets in Asia-Pacific and Latin America.
The market reports cover the Cancer Type, Treatment Type, Route of Administration, End User, Distribution Channel, and region segment.
Asia Pacific is the fastest-growing region in the market.
| 1.Executive Summary |
| 2.Global Thyroid Cancer Treatment Market Introduction |
| 2.1.Global Thyroid Cancer Treatment Market - Taxonomy |
| 2.2.Global Thyroid Cancer Treatment Market - Definitions |
| 2.2.1.Cancer Type |
| 2.2.2.Treatment Type |
| 2.2.3.Route of Administration |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Thyroid Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Thyroid Cancer Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Thyroid Cancer Treatment Market By Cancer Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Papillary Thyroid Cancer (PTC) |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Follicular Thyroid Cancer (FTC) |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Medullary Thyroid Cancer (MTC) |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Anaplastic Thyroid Cancer (ATC) |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Thyroid Cancer Treatment Market By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Surgery |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Radioactive Iodine Therapy |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Thyroid Hormone Therapy |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. External Beam Radiation Therapy |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Chemotherapy |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Targeted Therapy |
| 6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Thyroid Cancer Treatment Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Intravenous |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Thyroid Cancer Treatment Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Specialty Clinics |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Cancer Treatment Centers |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Ambulatory Surgical Centers |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Academic & Research Institutes |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.Global Thyroid Cancer Treatment Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Cancer Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Papillary Thyroid Cancer (PTC) |
| 10.1.2.Follicular Thyroid Cancer (FTC) |
| 10.1.3.Medullary Thyroid Cancer (MTC) |
| 10.1.4.Anaplastic Thyroid Cancer (ATC) |
| 10.1.5.Others |
| 10.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Surgery |
| 10.2.2.Radioactive Iodine Therapy |
| 10.2.3.Thyroid Hormone Therapy |
| 10.2.4.External Beam Radiation Therapy |
| 10.2.5.Chemotherapy |
| 10.2.6.Targeted Therapy |
| 10.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Intravenous |
| 10.3.3.Others |
| 10.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Specialty Clinics |
| 10.4.3.Cancer Treatment Centers |
| 10.4.4.Ambulatory Surgical Centers |
| 10.4.5.Academic & Research Institutes |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Papillary Thyroid Cancer (PTC) |
| 11.1.2.Follicular Thyroid Cancer (FTC) |
| 11.1.3.Medullary Thyroid Cancer (MTC) |
| 11.1.4.Anaplastic Thyroid Cancer (ATC) |
| 11.1.5.Others |
| 11.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Surgery |
| 11.2.2.Radioactive Iodine Therapy |
| 11.2.3.Thyroid Hormone Therapy |
| 11.2.4.External Beam Radiation Therapy |
| 11.2.5.Chemotherapy |
| 11.2.6.Targeted Therapy |
| 11.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Intravenous |
| 11.3.3.Others |
| 11.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Specialty Clinics |
| 11.4.3.Cancer Treatment Centers |
| 11.4.4.Ambulatory Surgical Centers |
| 11.4.5.Academic & Research Institutes |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Papillary Thyroid Cancer (PTC) |
| 12.1.2.Follicular Thyroid Cancer (FTC) |
| 12.1.3.Medullary Thyroid Cancer (MTC) |
| 12.1.4.Anaplastic Thyroid Cancer (ATC) |
| 12.1.5.Others |
| 12.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Surgery |
| 12.2.2.Radioactive Iodine Therapy |
| 12.2.3.Thyroid Hormone Therapy |
| 12.2.4.External Beam Radiation Therapy |
| 12.2.5.Chemotherapy |
| 12.2.6.Targeted Therapy |
| 12.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Intravenous |
| 12.3.3.Others |
| 12.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Specialty Clinics |
| 12.4.3.Cancer Treatment Centers |
| 12.4.4.Ambulatory Surgical Centers |
| 12.4.5.Academic & Research Institutes |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Papillary Thyroid Cancer (PTC) |
| 13.1.2.Follicular Thyroid Cancer (FTC) |
| 13.1.3.Medullary Thyroid Cancer (MTC) |
| 13.1.4.Anaplastic Thyroid Cancer (ATC) |
| 13.1.5.Others |
| 13.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Surgery |
| 13.2.2.Radioactive Iodine Therapy |
| 13.2.3.Thyroid Hormone Therapy |
| 13.2.4.External Beam Radiation Therapy |
| 13.2.5.Chemotherapy |
| 13.2.6.Targeted Therapy |
| 13.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Intravenous |
| 13.3.3.Others |
| 13.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Specialty Clinics |
| 13.4.3.Cancer Treatment Centers |
| 13.4.4.Ambulatory Surgical Centers |
| 13.4.5.Academic & Research Institutes |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Thyroid Cancer Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Cancer Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Papillary Thyroid Cancer (PTC) |
| 14.1.2.Follicular Thyroid Cancer (FTC) |
| 14.1.3.Medullary Thyroid Cancer (MTC) |
| 14.1.4.Anaplastic Thyroid Cancer (ATC) |
| 14.1.5.Others |
| 14.2. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Surgery |
| 14.2.2.Radioactive Iodine Therapy |
| 14.2.3.Thyroid Hormone Therapy |
| 14.2.4.External Beam Radiation Therapy |
| 14.2.5.Chemotherapy |
| 14.2.6.Targeted Therapy |
| 14.3. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Intravenous |
| 14.3.3.Others |
| 14.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Specialty Clinics |
| 14.4.3.Cancer Treatment Centers |
| 14.4.4.Ambulatory Surgical Centers |
| 14.4.5.Academic & Research Institutes |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Illumina, Inc. |
| 15.2.2.Siemens AG |
| 15.2.3.Abbott Laboratories |
| 15.2.4.Bio Rad Laboratories Inc. |
| 15.2.5.GE Healthcare |
| 15.2.6.Hoffmann-La Roche Ltd. |
| 15.2.7.Koninklijke Philips N.V. |
| 15.2.8.Thermo Fisher Scientific Inc. |
| 15.2.9.Toshiba Medical Systems Corporation |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
